Research Analysts Issue Forecasts for NTLA FY2026 Earnings

Key Points

• Brookline Capital Markets lowered its FY2026 EPS forecast for Intellia Therapeutics to a loss of $2.92 per share from a loss of $2.84, compared with the broader analyst consensus of a $3.21 loss.
• Intellia reported a quarterly loss of $0.91 per share, missing the $0.80-loss consensus, while revenue of $7.16 million fell short of expectations and declined 47.8% year over year.
• Analyst views remain mixed: MarketBeat reports an average rating of Hold and a consensus price target of $21.44, with ratings ranging from Sell to Strong Buy.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Research analysts at Brookline Capital Markets decreased their FY2026 earnings per share estimates for shares of Intellia Therapeutics in a note issued to investors on Thursday, November 5th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings per share of ($2.92) for the year, down from their prior estimate of ($2.84). The consensus estimate for Intellia Therapeutics' current full-year earnings is ($3.21) per share. Brookline Capital Markets also issued estimates for Intellia Therapeutics' FY2029 earnings at $13.90 EPS and FY2030 earnings at $23.26 EPS.

NTLA has been the topic of a number of other research reports. Barclays assumed coverage on Intellia Therapeutics in a research note on Tuesday, October 6th. They issued an "underweight" rating and a $8.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Intellia Therapeutics in a research note on Thursday, October 15th. Wedbush upped their price objective on Intellia Therapeutics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Wednesday, September 9th. Evercore upgraded Intellia Therapeutics from a "hold" rating to an "outperform" rating and set a $24.00 price objective on the stock in a research report on Friday, August 7th. Finally, Citigroup reissued a "market outperform" rating on shares of Intellia Therapeutics in a report on Tuesday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have issued a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $21.44.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $12.11 on Tuesday. Intellia Therapeutics has a 52-week low of $7.95 and a 52-week high of $18.48. The firm has a fifty day moving average of $12.08 and a 200 day moving average of $13.04. The firm has a market capitalization of $1.70 billion, a PE ratio of -3.61 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The company had revenue of $7.16 million for the quarter, compared to analysts' expectations of $9.74 million. During the same quarter last year, the business posted ($0.92) EPS. The business's quarterly revenue was down 47.8% compared to the same quarter last year.

Institutional Trading of Intellia Therapeutics

Several institutional investors have recently added to or reduced their stakes in NTLA. Nykredit A S bought a new position in shares of Intellia Therapeutics during the second quarter valued at about $33,000. Freestone Grove Partners LP purchased a new position in shares of Intellia Therapeutics in the second quarter worth about $33,000. Integrated Wealth Concepts LLC purchased a new position in shares of Intellia Therapeutics in the second quarter worth about $34,000. Farther Finance Advisors LLC lifted its stake in shares of Intellia Therapeutics by 289.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,144 shares of the company's stock valued at $26,000 after acquiring an additional 1,594 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in shares of Intellia Therapeutics by 267.0% in the 3rd quarter. Parallel Advisors LLC now owns 2,268 shares of the company's stock valued at $27,000 after acquiring an additional 1,650 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Intellia Therapeutics

In related news, CEO John M. Leonard sold 9,000 shares of Intellia Therapeutics stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $11.99, for a total value of $107,910.00. Following the transaction, the chief executive officer owned 1,138,064 shares in the company, valued at $13,645,387.36. This trade represents a 0.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.50% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA.

Its research includes in vivo therapies, which are designed to edit genes inside a patient's body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia's investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.